Y-Biologics, Inc. (KOSDAQ:338840)

South Korea flag South Korea · Delayed Price · Currency is KRW
19,790
+100 (0.51%)
At close: Oct 28, 2025
0.51%
Market Cap297.19B
Revenue (ttm)5.96B
Net Income (ttm)-6.19B
Shares Out14.95M
EPS (ttm)-499.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume272,196
Average Volume490,848
Open19,700
Previous Close19,690
Day's Range19,430 - 20,200
52-Week Range5,330 - 20,950
Betan/a
RSI73.50
Earnings Daten/a

About Y-Biologics

Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers. Y-Biologics, Inc. was incorporated in 2007 and is headquar... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 338840
Full Company Profile

Financial Performance

In 2024, Y-Biologics's revenue was 5.76 billion, an increase of 65.64% compared to the previous year's 3.48 billion. Losses were -6.44 billion, -69.14% less than in 2023.

Financial Statements

News

There is no news available yet.